Consistent Supply of High-Quality Products
First written in FY2017-Q1. 29 of 30 entries say "Restated". Latest entry: 2026-07-31.
The whole theme swung hardest in 2024: 2 of 22 companies on the "Worse" side.
19 other companies' latest entry also says "Restated".
- 2026-07-31RestatedEarnings
「Under these circumstances, we have made the stable, continuous supply of high-quality products a priority,」
The company reaffirmed through timely disclosure its policy of prioritizing the stable, continuous supply of high-quality products. - FY2026-H1RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
We continue to pursue a policy of prioritizing the consistent, stable supply of high-quality products and implementing measures in sales, production and research and development. - FY2025RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
The Company continues this policy of prioritizing the consistent, stable supply of high-quality products. - FY2025-H1RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
We continue to pursue a policy of prioritizing the consistent, stable supply of high-quality products and implementing measures in sales, production and research and development. - FY2024-Q3RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
We continue to pursue a policy of prioritizing the consistent, stable supply of high-quality products and implementing measures in sales, production and research and development. - FY2024-Q2RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
We continue to pursue a policy of prioritizing the consistent, stable supply of high-quality products and implementing measures in sales, production and research and development. - FY2024-Q1RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
We continue to pursue a policy of prioritizing the consistent, stable supply of high-quality products and implementing measures in sales, production and research and development. - FY2023-Q3RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
We continue to pursue a policy of prioritizing the consistent, stable supply of high-quality products and implementing measures in sales, production and research and development. - FY2023-Q2RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
The Company continues this policy of prioritizing the consistent, stable supply of high-quality products. - FY2022RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
The Company continues this policy of prioritizing the consistent, stable supply of high-quality products. - FY2022-Q2RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
We continue to pursue a policy of prioritizing the consistent, stable supply of high-quality products and implementing measures in sales, production and research and development. - FY2022-Q1RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
We continue to pursue a policy of prioritizing the consistent, stable supply of high-quality products and implementing measures in sales, production and research and development. - FY2021RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
The Company continues this policy of prioritizing the consistent, stable supply of high-quality products. - FY2021-Q3RestatedAnnual report
「Against this backdrop, the Company conducted its business activities while all employees worked to prevent the spread of infection, identifying the stable supply of products as its highest priority.」
The Company continues to prioritize preventing the spread of infection and maintaining a stable supply of products. - FY2021-Q2RestatedAnnual report
「Against this backdrop, the Company conducted its business activities while all employees worked to prevent the spread of infection, identifying the stable supply of products as its highest priority.」
The Company continues to prioritize preventing the spread of COVID-19 and maintaining a stable supply of products. - FY2021-Q1RestatedAnnual report
「Against this backdrop, the Company conducted its business activities while all employees worked to prevent the spread of infection, identifying the stable supply of products as its highest priority.」
The Company continues to prioritize preventing the spread of COVID-19 and maintaining a stable supply of products. - FY2020RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
The Company continues this policy of prioritizing the consistent, stable supply of high-quality products. - FY2020-Q3RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
The Company continues to pursue a policy of prioritizing the consistent, stable supply of high-quality products. - FY2019RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
The Company continues this policy of prioritizing the consistent, stable supply of high-quality products. - FY2019-Q3RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
The Company continues to pursue a policy of prioritizing the consistent, stable supply of high-quality products. - FY2019-Q2RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
The Company continues to pursue a policy of prioritizing the consistent, stable supply of high-quality products. - FY2019-Q1RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
The Company continues to pursue a policy of prioritizing the consistent, stable supply of high-quality products. - FY2018RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with medical professionals, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
The Company continues to pursue a policy of prioritizing the consistent, stable supply of high-quality products. - FY2018-Q3RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with users, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
The Company continues to pursue a policy of prioritizing the consistent, stable supply of high-quality products. - FY2018-Q2RestatedAnnual report
「Against this backdrop, the Company identified the consistent, stable supply of high-quality products as a priority and worked to promote sales activities closely aligned with users, establish a cost-competitive production system while maintaining quality, and strengthen research and development of innovative products.」
The Company continues to pursue a policy of prioritizing the consistent, stable supply of high-quality products. - FY2018-Q1RestatedAnnual report
「The Company has made the consistent supply of high-quality products a priority.」
The Company continues to make the consistent supply of high-quality products a priority. - FY2017RestatedAnnual report
「The Company has made the consistent supply of high-quality products a priority.」
The Company continues to make the consistent supply of high-quality products a priority. - FY2017-Q3RestatedAnnual report
「The Company has made the consistent supply of high-quality products a priority,」
The Company continues to make the consistent supply of high-quality products a priority. - FY2017-Q2RestatedAnnual report
「The Company has made the consistent supply of high-quality products a priority.」
The Company continues to make the consistent supply of high-quality products a priority. - FY2017-Q1First statedAnnual report
「The Company has made the consistent supply of high-quality products a priority.」
The Company has made the stable supply of high-quality products a priority.